Archived explainer. For the current picture see today's TEM page.
TEMPUS AI INC A (TEM) is drawing unusual attention today. Our newswire has captured 21 stories on TEM across 13 sources in the last 36 hours, with AI sentiment reading bullish (avg 58/100).
Tempus AI Inc A (TEM) is moving sharply lower in early trading, down more than 10% from its opening price. The stock has been pressured by the announcement of a $1.5 billion all-stock acquisition of Personalis, a genomics company, which has raised concerns among investors about valuation and near-term financial implications. The deal, disclosed on July 20, 2026, has triggered a sharp intraday selloff, with the stock falling as low as $47.00 before stabilizing slightly.
Tempus AI announced a definitive merger agreement to acquire Personalis, a move intended to strengthen its position in minimal residual disease (MRD) testing and expand its biopharma data capabilities. The acquisition is expected to bolster Tempus AI’s precision oncology business, according to Morgan Stanley, which still maintains a positive view of the strategic rationale. However, the all-stock nature of the deal and the valuation have drawn scrutiny. Needham analysts have called the market’s reaction a “misread,” while Jefferies has reissued a cautious stance. The CEO of Tempus AI, Ryan Fukushima, has sold shares in two recent transactions, and other insiders have also been offloading stock.
The stock opened at $52.87, a modest 0.8% gap up from the previous close, but quickly reversed course. By 8:35 AM ET, it had fallen to $47.00, a level that marked a significant drop from its 52-week high of $104.32. The session has seen a volume of 7.8 million shares, which is 1.3 times the 3-month average. The stock’s beta of 3.46 suggests it is highly volatile, and its current price is trading near the lower end of its 52-week range. Recent insider sales totaling $23.3 million in the last 90 days may also be influencing sentiment.
The company is not scheduled to report earnings in the near term. Investors will be watching for further analyst commentary and how the market digests the acquisition’s long-term strategic value. Coverage breadth remains broad, with 21 stories from 13 sources in the last 36 hours.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
Tempus AI, Inc. Class A ( ($TEM) ) just unveiled an announcement. On July 20, 2026, Tempus AI, Inc. signed a definitive merger agreement to acquire genomics company...
Jefferies reiterates Tempus AI stock rating on acquisition concerns
Tempus AI ($TEM) stock fell about 8% on Monday after the health technology company said it will acquire biotechnology company Personalis ($PSNL) in an all-stock dea...
The brokerage said the acquisition strengthens Tempus AI’s precision oncology business, though near-term financials are less compelling.
Tempus AI stock maintains Buy rating after Personalis acquisition
Needham reiterates Tempus AI stock rating after Personalis deal
Tempus AI (NASDAQ:TEM) executives said the company’s planned acquisition of Personalis is intended to strengthen its position in minimal residual disease, or MRD, testing, while expanding its biopharma data and profiling capabilities. On a call with analysts, Tempus said it agreed to acquire all ou
Tempus AI pledged to buy cancer diagnostics outfit Personalis for $1.5 billion on Monday. But shares of both medtech companies skidded.
More on TEM: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier TEM move explainers: 2026-07-22 · 2026-07-21 · 2026-07-20